Diabetes is one of the four major types of non-communicable diseases (NCDs) that contribute most to morbidity and mortality worldwide. The prevalence of diabetes is increasing in Bangladesh. In 2021, the International Diabetes Federation estimated that 13.1 million people were living with diabetes in Bangladesh and that this is expected to almost double by 2025.
When managing diabetes, one of the primary concerns for healthcare professionals remains how to effectively reduce HbA1c without triggering other comorbidities. SGLT2 (sodium-glucose cotransporter-2) inhibitors, in this context, play a central role in the diabetes treatment regimen. Synovia Pharma has provided groundbreaking new and innovative solutions to meet the unmet needs of Bangladeshi patients, a press release says.
Distinguished Medical Professor AK Azad Khan, National Professor and President of Bangladesh Diabetes Association graced the launch event as the chief guest. Prof. Md Faruque Pathan, Professor of Endocrinology, BIRDEM General Hospital chaired the program where Prof. SM Ashrafuzzaman – Professor and President of Bangladesh Endocrine Society was present as a special guest.
Prof. Indrajit Prasad, Head of Endocrinology, Dhaka Medical College Hospital presented “Outcome-Based Diabetes Management of Cardiovascular Disease” and Prof. Shamim Ahmed, National Institute of Kidney Diseases and Urology (NIKDU) presented “Kidney Protection Focused Diabetes Management”.